China's Rainmed Medical H1 revenue rises, net loss narrows

Rainmed Medical

31/08/2026 11:08

Overview
China medical device maker's H1 revenue rose 41% yr/yr, driven by caFFR system sales
Net loss attributable to shareholders narrowed to RMB22 mln, reflecting ongoing R&D and commercialization costs
No interim dividend declared for the period
     

Result Drivers
caFFR SYSTEM SALES - Revenue growth was mainly driven by sales of FlashPressure caFFR pressure transducer
NEW PRODUCT CONTRIBUTION - Coronary artery cutting balloon product began contributing to revenue, aided by inclusion in national centralized bulk procurement scope
ONGOING EXPENSES - Net loss was mainly attributable to ongoing expenses for research and development, manufacturing and commercialization

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 14.70 mln
 
H1 Net Loss Attributable
 
RMB 22 mln
 

Reuters Recommended Reads
Aug 31 - China's HeartCare Medical H1 revenue surges on stroke segment growth
Aug 31 - China's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Aug 28 - China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-31/8725fd71-9239-490f-a542-d86f053c981b.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)